As shown in Fig. 1B, TOP2A expression was higher in adrenocortical carcinoma (ACC), cervical squamous cell carcinoma (CESC), diffuse large B-cell lymphoma (DLBC), lower grade glioma (LGG), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), sarcoma (SARC), skin cutaneous melanoma (SKCM), thymoma (THYM) and uterine carcinosarcoma (UCS, p < 0.05 in PCPG, and all other p values < 0.001). This evidence concerns the gene TOP2A and central nervous system cancer.